Stocks and Investing Stocks and Investing
Tue, June 15, 2021
Mon, June 14, 2021

Robyn Karnauskas Maintained (VRTX) at Strong Buy with Increased Target to $331 on, Jun 14th, 2021


Published on 2024-10-27 16:58:41 - WOPRAI, Robyn Karnauskas
  Print publication without navigation


Robyn Karnauskas of Truist Securities, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Strong Buy with Increased Target from $305 to $331 on, Jun 14th, 2021.

Robyn has made no other calls on VRTX in the last 4 months.



There are 10 other peers that have a rating on VRTX. Out of the 10 peers that are also analyzing VRTX, 1 agrees with Robyn's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $205 on, Friday, June 11th, 2021


These are the ratings of the 9 analyists that currently disagree with Robyn


  • Alethia Young of "Cantor Fitzgerald" Maintained at Buy with Decreased Target to $281 on, Friday, June 11th, 2021
  • Brian Abrahams of "RBC Capital" Maintained at Buy with Decreased Target to $242 on, Friday, June 11th, 2021
  • Brian Skorney of "Baird" Maintained at Buy with Decreased Target to $240 on, Friday, June 11th, 2021
  • Mohit Bansal of "Citigroup" Maintained at Strong Buy with Decreased Target to $285 on, Friday, June 11th, 2021
  • Paul Matteis of "Stifel" Maintained at Strong Buy with Decreased Target to $244 on, Friday, June 11th, 2021
  • Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Decreased Target to $307 on, Friday, June 11th, 2021
  • Gena Wang of "Barclays" Maintained at Buy with Decreased Target to $285 on, Friday, June 11th, 2021
  • Colin Bristow of "UBS" Maintained at Strong Buy with Increased Target to $279 on, Wednesday, May 12th, 2021
  • Liisa Bayko of "Evercore ISI Group" Maintained at Buy and Held Target at $260 on, Monday, May 3rd, 2021
Contributing Sources